CommercialPrior AuthMedium impact
Pharmacy Medical Policy Updates
Blue Cross Blue Shield of Kansas·KS · Rheumatology, Dermatology, Allergy & Immunology +3 more·Pharmacy
Effective date
Jun 1, 2024
We identified it
Jun 19, 2026
Summary
BCBS Kansas updated pharmacy medical policies for multiple specialty medications effective June 1, 2024, including drugs for autoimmune conditions, lupus, and rare diseases. These updates likely involve changes to prior authorization requirements, coverage criteria, or formulary status for affected medications.
Action Required
By June 1, 2024: Billing and clinical teams should review updated prior authorization requirements for the listed specialty medications (Cibinqo, IL-13 Antagonists, IL-4 Inhibitors, IL-5 Inhibitors, Zoryve, IL-1 Inhibitors, Lupus medications, Xolair, Soliris/Ultomiris, Empaveli, Agamree, Emflaza, and Fabhalta) by visiting https://www.bcbsks.com/providers/precertification-prior-authorization and selecting the appropriate medication list. Update prior authorization workflows and staff training for these medications to prevent claim denials.